JonesResearch downgraded Chimerix (CMRX) to Hold from Buy with an $8.55 price target after Jazz Pharmaceuticals (JAZZ) announced a deal to acquire the company for $8.55 per share or $935M in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMRX:
- Strategic Acquisition and NDA Submission Boost Chimerix’s Market Potential
- Cautious Outlook on Chimerix Amid Acquisition and Uncertainties in Drug Approval
- Chimerix downgraded to Hold from Buy at Jefferies
- CrowdStrike reports Q4 beat, Jazz to acquire Chimerix: Morning Buzz
- Hold Rating Issued Amidst Chimerix Acquisition by Jazz Pharmaceuticals